Home / Going-concern warnings / Adverum Biotechnologies, Inc.
Filed 2025-08-12 · Form 10-Q · Accession 0001628280-25-039761 micro
Price before filing: $2.24 (2025-08-11 close, split/dividend-adjusted)
Market cap at flag: $51.9M (2025-08-12) · Latest: $102.4M (2025-12-09)
| Window | ADVM | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | +40.2% | +3.4% | +36.8% | 2025-09-11 |
| 90 days | +91.1% | +7.5% | +83.6% | 2025-11-10 |
| 180 days | n/a | n/a | n/a | no price after 2025-12-09 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
90 days before the flag: 3 insiders sold $26K (3 sales)
30 days after: none reported.
| Date | Insider | Type | Shares | Price | Value | 10b5-1 plan | Source |
|---|---|---|---|---|---|---|---|
| 2025-05-15 | Fischer Laurent CEO, PRESIDENT AND DIRECTOR, Director | Sale | 9,126 | $2.00 | $18K | no | Form 4 |
| 2025-05-15 | Seyedkazemi Setareh CHIEF DEVELOPMENT OFFICER | Sale | 924 | $2.00 | $2K | no | Form 4 |
| 2025-05-15 | Soparkar Peter CHIEF OPERATING OFFICER | Sale | 2,960 | $2.00 | $6K | no | Form 4 |
| 2025-08-12: red flag filed | |||||||
Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2025-05-14 to 2025-09-11. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.
"Exhibits 73 SIGNATURES 75 2 Table of Contents RISK FACTORS SUMMARY Investing in common stock involves numerous risks, including the risks described in Part II, Item 1A "Risk Factors" of this Quarterly Report on Form 10-Q. Below are some of these risks, any one of which could materially adversely affect our business, financial condition, results of operations, and prospects. • There is substantial doubt regarding our..."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-Q (period 2025-06-30)
Why this score: quarterly (unaudited) disclosure
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.